Retrospective analysis reveals dupilumab improves symptoms and histologic outcomes in eosinophilic colitis patients, suggesting a new treatment avenue.
INTRODUCTION: Eosinophilic colitis (EoC) currently has limited options to induce histologic and clinical remission. Dupilumab is a human monoclonal antibody against the interleukin-4 receptor ɑ subunit effective in eosinophilic esophagitis (EoE) and other non-EoE eosinophilic gastrointestinal disorders (non-EoE EGIDs). METHODS: We conducted a retrospective chart review to assess the histoclinical response of patients with EoC treated with dupilumab. RESULTS: Of 4 included patients, all 4 improved histologically, with 3 patients attaining histologic remission. All patients’ symptom scores significantly improved, and 1 patient was asymptomatic on dupilumab. DISCUSSION: This retrospective case series provides preliminary evidence that dupilumab may be an effective treatment option for EoC.
No takes yet. Share an insight, caveat, or question.
Sia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: